Literature DB >> 26452581

(68)Ga-PSMA-HBED-CC PET/CT: where molecular imaging has an edge over morphological imaging.

Felix M Mottaghy1,2, Florian F Behrendt3, Frederik A Verburg3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26452581     DOI： 10.1007/s00259-015-3212-5

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  34 in total

1.  [¹⁷⁷Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer.

Authors:  Clemens Kratochwil; Frederik L Giesel; Matthias Eder; Ali Afshar-Oromieh; Martina Benešová; Walter Mier; Klaus Kopka; Uwe Haberkorn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-01-09       Impact factor: 9.236

2.  The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions.

Authors:  Ali Afshar-Oromieh; Henrik Hetzheim; Clemens Kratochwil; Martina Benesova; Matthias Eder; Oliver C Neels; Michael Eisenhut; Wolfgang Kübler; Tim Holland-Letz; Frederik L Giesel; Walter Mier; Klaus Kopka; Uwe Haberkorn
Journal:  J Nucl Med       Date:  2015-08-20       Impact factor: 10.057

3.  Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature.

Authors:  S S Chang; V E Reuter; W D Heston; N H Bander; L S Grauer; P B Gaudin
Journal:  Cancer Res       Date:  1999-07-01       Impact factor: 12.701

4.  Biokinetics and dosimetry in patients administered with (111)In-DOTA-Tyr(3)-octreotide: implications for internal radiotherapy with (90)Y-DOTATOC.

Authors:  M Cremonesi; M Ferrari; S Zoboli; M Chinol; M G Stabin; F Orsi; H R Maecke; E Jermann; C Robertson; M Fiorenza; G Tosi; G Paganelli
Journal:  Eur J Nucl Med       Date:  1999-08

5.  Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy.

Authors:  Ken Herrmann; Christina Bluemel; Martina Weineisen; Margret Schottelius; Hans-Jürgen Wester; Johannes Czernin; Uta Eberlein; Seval Beykan; Constantin Lapa; Hubertus Riedmiller; Markus Krebs; Saskia Kropf; Andreas Schirbel; Andreas K Buck; Michael Lassmann
Journal:  J Nucl Med       Date:  2015-04-16       Impact factor: 10.057

6.  Prostate-specific membrane antigen expression in normal and malignant human tissues.

Authors:  D A Silver; I Pellicer; W R Fair; W D Heston; C Cordon-Cardo
Journal:  Clin Cancer Res       Date:  1997-01       Impact factor: 12.531

7.  PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions.

Authors:  A Afshar-Oromieh; A Malcher; M Eder; M Eisenhut; H G Linhart; B A Hadaschik; T Holland-Letz; F L Giesel; C Kratochwil; S Haufe; U Haberkorn; C M Zechmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-11-24       Impact factor: 9.236

8.  Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours.

Authors:  I Buchmann; M Henze; S Engelbrecht; M Eisenhut; A Runz; M Schäfer; T Schilling; S Haufe; T Herrmann; U Haberkorn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-05-23       Impact factor: 9.236

9.  PSMA PET/CT with Glu-urea-Lys-(Ahx)-[⁶⁸Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer.

Authors:  Frederik L Giesel; H Fiedler; M Stefanova; F Sterzing; M Rius; K Kopka; J H Moltz; A Afshar-Oromieh; P L Choyke; U Haberkorn; C Kratochwil
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-07-11       Impact factor: 9.236

10.  Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study.

Authors:  Hojjat Ahmadzadehfar; Kambiz Rahbar; Stefan Kürpig; Martin Bögemann; Michael Claesener; Elisabeth Eppard; Florian Gärtner; Sebastian Rogenhofer; Michael Schäfers; Markus Essler
Journal:  EJNMMI Res       Date:  2015-06-20       Impact factor: 3.138
View more
  9 in total

1.  The reconstruction algorithm used for [68Ga]PSMA-HBED-CC PET/CT reconstruction significantly influences the number of detected lymph node metastases and coeliac ganglia.

Authors:  Thomas Krohn; Anita Birmes; Oliver H Winz; Natascha I Drude; Felix M Mottaghy; Florian F Behrendt; Frederik A Verburg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-11-29       Impact factor: 9.236

2.  Preclinical Comparative Study of (68)Ga-Labeled DOTA, NOTA, and HBED-CC Chelated Radiotracers for Targeting PSMA.

Authors:  Sangeeta Ray Banerjee; Zhengping Chen; Mrudula Pullambhatla; Ala Lisok; Jian Chen; Ronnie C Mease; Martin G Pomper
Journal:  Bioconjug Chem       Date:  2016-05-09       Impact factor: 4.774

3.  A new perspective for nuclear medicine: expanding the indications for PSMA targeted imaging and therapy.

Authors:  Frederik A Verburg; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-07-04       Impact factor: 9.236

4.  Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with (68)Ga-PSMA-HBED-CC than with (18)F-Fluoroethylcholine PET/CT.

Authors:  David Pfister; Daniel Porres; Axel Heidenreich; Isabel Heidegger; Ruth Knuechel; Florian Steib; Florian F Behrendt; Frederik A Verburg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-03-19       Impact factor: 9.236

5.  Impact of 68Ga-PSMA PET/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy.

Authors:  Christina Bluemel; Fraenze Linke; Ken Herrmann; Iva Simunovic; Matthias Eiber; Christian Kestler; Andreas K Buck; Andreas Schirbel; Thorsten A Bley; Hans-Juergen Wester; Daniel Vergho; Axel Becker
Journal:  EJNMMI Res       Date:  2016-10-26       Impact factor: 3.138

6.  Screening for Circulating Tumour Cells Allows Early Detection of Cancer and Monitoring of Treatment Effectiveness: An Observational Study

Authors:  Karin Ried; Peter Eng; Avni Sali
Journal:  Asian Pac J Cancer Prev       Date:  2017-08-27

7.  PSMA expression by microvasculature of thyroid tumors - Potential implications for PSMA theranostics.

Authors:  Andrey Bychkov; Usanee Vutrapongwatana; Supatporn Tepmongkol; Somboon Keelawat
Journal:  Sci Rep       Date:  2017-07-12       Impact factor: 4.379

8.  PSMA-PET for Lymph Node Detection in Recurrent Prostate Cancer: How do we use the Magic Bullet?

Authors:  Tobias Maurer; Declan G Murphy; Michael S Hofman; Matthias Eiber
Journal:  Theranostics       Date:  2017-05-15       Impact factor: 11.556

9.  Extraordinary Claims Don't always Require Extraordinary Evidence, but They Do Require Good Quality Evidence.

Authors:  David Hawkes
Journal:  Asian Pac J Cancer Prev       Date:  2019-07-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.